The most popular targets so far in clinical trials have been EGFRvIII, HER2, IL13Rα2, GD2, B7-H3, chlorotoxin, and EPHA2 (see Table 2 for a list of CAR T trials in glioma/GBM and other primary brain tumors on clinicaltrials.gov). This evidence concerns the gene ERBB2 and glioma.